Corneal Graft RejectionNCT05009407
CD160 Expression in Corneal Vessels
An observational study of Corneal Graft Rejection and CD160, run by CHU de Reims at 1 site in France.
Trial summary
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Corneal Graft Rejection, CD160, Angiogenesis
- What is being tested?
- Immunohistochemistry and clinical analyses on patients and corneas
- How many people
- 43 participants
- Where
- 1 siteFrance
- Study dates
- 21 Apr 2021to 22 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 18-year-old or more patients enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
Who may be able to join
- 18-year-old or more patients
- enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
- considered able to give an informed written consent exclusion criteria :
- none
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: CD160 Ans Corneal Graft: Expression in Corneal Vessels
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis
Read the detailed description
After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included.
Routine general and eye examination including cornea photographs will be performed.
During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.
- Conditions
- Corneal Graft Rejection, CD160, Angiogenesis, Lymphangiogenesis
- Being tested
- Immunohistochemistry and clinical analyses on patients and corneas
- Keywords
- Corneal Graft Rejection, CD160, Angiogenesis, lymphangiogenesis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Immunohistochemistry and clinical analyses on patients and corneasBiological
Immunohistochemistry and clinical analyses on patients and corneas
| Study group | Role | What they receive |
|---|---|---|
| HOSTS | patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor Receives: Biological: Immunohistochemistry and clinical analyses on patients and corneas | |
| DONORS | grafts from donors that would be analyzed Receives: Biological: Immunohistochemistry and clinical analyses on patients and corneas |
What is being measured
The primary outcome is the main question the study is designed to answer.
Micro-vascular densities
neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160
Measured: 1 year
Secondary outcomes (2)
Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA
Measured: 1 year
Evaluation of clinical blood vascular densities on photographs with help of ImageJ software
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2021
- Study start21 Apr 2021
- Primary completion22 Dec 2025
- Study completion22 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Corneal Graft RejectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- CHU de Reims
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05009407
- Sponsor's protocol ID
- PO21062
- Status last verified
- Feb 2026
- First submitted
- 3 Aug 2021
- Last updated
- 19 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CD160 Ans Corneal Graft: Expression in Corneal Vessels
- ClinicalTrials.gov ID
- NCT05009407
- Acronym / sponsor ID
- PO21062
- Conditions
- Corneal Graft Rejection, CD160, Angiogenesis, Lymphangiogenesis
- Keywords
- Corneal Graft Rejection, CD160, Angiogenesis, lymphangiogenesis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 43 participants (actual)
- Lead sponsor
- CHU de ReimsUniversity, hospital or other
- Study start
- 21 Apr 2021 (actual)
- Primary completion
- 22 Dec 2025 (actual)
- Study completion
- 22 Dec 2025 (actual)
- First posted
- 17 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis
Detailed description
After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included.
Routine general and eye examination including cornea photographs will be performed.
During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HOSTS | – | Biological: Immunohistochemistry and clinical analyses on patients and corneaspatients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor |
| DONORS | – | Biological: Immunohistochemistry and clinical analyses on patients and corneasgrafts from donors that would be analyzed |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 18-year-old or more patients enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
Key inclusion criteria (4 listed)
- 18-year-old or more patients
- enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
- considered able to give an informed written consent exclusion criteria :
- none
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Immunohistochemistry and clinical analyses on patients and corneasImmunohistochemistry and clinical analyses on patients and corneas | Biological | DONORS, HOSTS |
Primary outcome
Micro-vascular densities
Time frame: 1 year
neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160
2 secondary outcomes
Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA
Time frame: 1 year
Evaluation of clinical blood vascular densities on photographs with help of ImageJ software
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Corneal Graft Rejection and CD160, run by CHU de Reims at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Micro-vascular densities (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.